Cold Spring Harbor Laboratory  
Contact Us | Faculty & Staff Directory

Harbor Transcript

 
 
 

Contact Public Affairs

We want to hear from you.
Contact Us

Follow us on

  facebook-icon twitter-icon instagram-icon3 youtube-icon wordpress-icon2
  rss-icon email-icon linkedin-icon flipboard icon

  appstore_icon_small_new

A drug called nusinersen (Spinraza) is now in the hands of doctors across the nation, who will use it, most urgently, to treat young children with a severe and potentially fatal illness called spinal muscular atrophy (SMA). The drug was conceived and tested over several years in mouse models of SMA by Professor Adrian Krainer, Ph.D., and his colleagues at Cold Spring Harbor Laboratory (CSHL) in collaboration with Dr. Frank Bennett and his team at Ionis Pharmaceuticals. News of the approval pleased the drug's developers and delighted parents of affected children. Read more
 
CSHL in the News

Fierce Biotech
Plus-sized fly could boost research aimed at treating hereditary obesity
January 12, 2017

Richmond Times-Dispatch

Lohmann: After a quarter-century, a dream comes true for Andrew and his buddies
January 8, 2017

MIT Technology Review
10 Breakthrough Technologies of 2016: Where Are They Now?
January 2, 2017

Wall Street Journal
Ionis and Biogen's Spinraza drug for spinal muscular atrophy wins FDA approval...


Read more...

  Latest News